Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 12/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2594029 | 0.84 | CYP17A1 (0.47) | CYP17A1CYP1A2IDO1CYP11B2CYP11B1 | |
| SCHEMBL2592210 | 0.78 | CYP17A1 (0.42) | CYP17A1CYP1A2IDO1CYP11B2CYP11B1 | |
| SCHEMBL2587151 | 0.78 | CYP17A1 (0.46) | CYP17A1CYP1A2CYP11B2CYP11B1PRKCZ | |
| SCHEMBL2588731 | 0.77 | CYP17A1 (1.00) | CYP17A1CYP1A2NPC1MAPTNFKB1 | |
| SCHEMBL14694367 | 0.77 | CYP17A1 (1.00) | CYP17A1CYP1A2NPC1MAPTNFKB1 | |
| SCHEMBL14694672 | 0.74 | CYP17A1 (0.73) | CYP17A1CYP1A2NPC1MAPTNFKB1 | |
| SCHEMBL12074902 | 0.73 | PRKCZ (0.69) | CYP17A1CYP1A2CYP11B2CYP11B1PRKCZ | |
| SCHEMBL2591802 | 0.71 | CYP17A1 (0.52) | CYP17A1CYP1A2CYP11B2CYP11B1PRKCZ | |
| SCHEMBL4562594 | 0.71 | CYP17A1 (1.00) | CYP17A1CYP1A2CYP11B1 | |
| SCHEMBL14694745 | 0.70 | CYP17A1 (0.69) | CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145419-B2 | Imidazopyridazinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-29 | — | — | US | claimed |
| EP-2563792-B1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL MYERS SQUIBB CO (US) | 2014-08-27 | — | — | EP | claimed |
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-21 | — | — | US | claimed |
| US-9145419-B2 | Imidazopyridazinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2563792-B1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL MYERS SQUIBB CO (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2563792-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | Bristol-Myers Squibb Company (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011137155-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | CYP2C19, CYP3A7, CYP2C18 | CYP17A1 54/4885CYP1A2 9/4885NPC1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.